Bayer faces pivotal test of $7.25 billion Roundup settlement in Missouri court
Bayer's Monsanto unit heads to a Missouri state court on Monday seeking approval of a $7.25 billion settlement that could resolve tens of thousands of U.S. lawsuits alleging that its popular weedkiller Roundup causes cancer.
Bayer Secures FDA Nod for Sevabertinib's First-Line Use in NSCLC
BAYRY's sevabertinib wins first-line NSCLC approval. The company advances BAY 3670549 into a phase II AFib study.
Bayer Aktiengesellschaft (BAYRY) Discusses Innovation Strategy and Progress on Five-Year Growth Framework in Crop Science Division Transcript
Bayer Aktiengesellschaft (BAYRY) Discusses Innovation Strategy and Progress on Five-Year Growth Framework in Crop Science Division Transcript
Bayer Crop Science Targets €3B Cash Flow by 2029 With Seeds-Led Growth
Bayer Aktiengesellschaft ETR: BAYN outlined progress on its Crop Science division's five-year framework at a 2026 innovation event in Iowa, reaffirming targets for above-market sales growth, a mid-20s clean EBITDA margin and more than €3 billion in free operating cash flow by 2029.
3 Large-Cap Stocks to Watch as Pharma Recovery Takes Hold
In the Large-Cap Pharmaceuticals industry, LLY, J&J and BAYRY are worth watching as the industry shows a strong recovery.
Bayer Aktiengesellschaft (BAYRY) Q2 2026 Earnings Call Transcript
Bayer Aktiengesellschaft (BAYRY) Q2 2026 Earnings Call Transcript
BAYRY Beats on Q2 Earnings, Crop Science Business Boosts Growth
Bayer tops Q2 estimates as Crop Science and fast-growing drugs offset pressure from patent-expired brands, while reaffirming its 2026 outlook.
Bayer Aktiengesellschaft Q2 Earnings Call Highlights
Bayer Aktiengesellschaft ETR: BAYN said first-half sales rose 3% on a currency- and portfolio-adjusted basis to €24.3 billion, as growth in Crop Science and Consumer Health offset pressure in parts of its pharmaceutical business. The company reiterated its full-year 2026 outlook and lowered its net financial debt target after a €3 billion equity investment from Apollo.
Bayer Swings to Net Profit on Smaller Litigation Charges
The company said its 2026 sales and earnings forecasts were unchanged when adjusted for currency changes, and that year-end net debt would be lower than originally projected.
Bayer: Debt Remains A Problem, Value Remains Compelling
Bayer Aktiengesellschaft remains undervalued despite a strong 18-month rally and ongoing operational improvements. I see upside potential supported by improving EBIT, robust pipeline assets, and technical breakout, though litigation and high debt persist. Litigation settlements and negative free cash flow weigh on the balance sheet, but recent Apollo investment and restructuring efforts provide some relief.
Apollo to Buy $3.4 Billion Stake in Bayer Contraceptives Business
The asset-management firm agreed to buy a minority stake in Bayer's long-acting reversible contraceptives business.
BAYRY Stock Surges 17% After Supreme Court Roundup Ruling
Bayer shares jump 17% after a Supreme Court ruling on Roundup litigation that could significantly reduce warning-based claims and litigation costs.
